


## Necrostatin 2

## Chemical Properties

|                   |  |
|-------------------|--|
| CAS No.:          | 852391-19-6  |
| Formula:          | C <sub>13</sub> H <sub>12</sub> ClN <sub>3</sub> O <sub>2</sub>        |
| Molecular Weight: | 277.71   |
| Appearance:       | N/A  |
| Storage:          | 0-4°C for short term (days to weeks), or -20°C for long term (months). |



## Biological Description

|                            |   |
|----------------------------|---|
| Description                | Necrostatin 2 is an effective necroptosis inhibitor. Necrostatin 2 is also a RIPK1 inhibitor. EC <sub>50</sub> for inhibition of necroptosis in FADD-deficient Jurkat T cells treated with TNF- $\alpha$ is 0.05 $\mu$ M.   |
| Targets(IC <sub>50</sub> ) | Necroptosis: None   |
| In vitro                   | Necrostatin 2 displays activity in a broad range of necroptosis cellular systems[1]. Necrostatin 2 at 30 $\mu$ M fully protects L929 cells from TNF- $\alpha$ -induced necroptosis. In addition to TNF- $\alpha$ , the pan-caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone (zVAD.fmk) has also been found to induce necrosis in L929 cells, which is efficiently inhibited by Necrostatin 2[2]. Evaluation of necroptosis inhibitory activity is performed using a FADD-deficient variant of human Jurkat T cells treated with TNF- $\alpha$ . Utilizing these conditions the cells efficiently undergo necroptosis, which is completely and selectively inhibited by Necrostatin 2 (EC <sub>50</sub> =50 nM). EC <sub>50</sub> for inhibition of necroptosis in FADD-deficient Jurkat T cells treated with TNF- $\alpha$ is 0.05 $\mu$ M[3]. |

## Solubility Information

|            |   |
|------------|---|
| Solubility | DMSO: 100 mg/mL (360.09 mM)<br>( < 1 mg/ml refers to the product slightly soluble or insoluble) |
|------------|---|

### Preparing Stock Solutions

|       | 1mg      | 5mg       | 10mg      |
|-------|----------|-----------|-----------|
| 1 mM  | 3.601 mL | 18.004 mL | 36.009 mL |
| 5 mM  | 0.72 mL  | 3.601 mL  | 7.202 mL  |
| 10 mM | 0.36 mL  | 1.8 mL    | 3.601 mL  |
| 50 mM | 0.072 mL | 0.36 mL   | 0.72 mL   |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. The storage conditions and period of the stock solution: - 80 °C for 6 months; - 20 °C for 1 month. Please use it as soon as possible.

Reference

1. Teng X, et al. Structure-activity relationship study of [1,2,3]thiadiazole necroptosis inhibitors. Bioorg Med Chem Lett. 2007 Dec 15;17(24):6836-40.
2. Jagtap PG, et al. Structure-activity relationship study of tricyclic necroptosis inhibitors. J Med Chem. 2007 Apr 19;50(8):1886-95.
3. Teng X, et al. Structure-activity relationship study of novel necroptosis inhibitors. Bioorg Med Chem Lett. 2005 Nov 15;15(22):5039-44.
4. Takahashi N, et al. Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease models. Cell Death Dis. 2012 Nov 29;3:e437.

Inhibitors · Natural Compounds · Compound Libraries

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use.

Tel:781-999-4286

E-mail:info@targetmol.com

Address:36 Washington Street,Wellesley Hills,MA 02481